



## Post Authorisation Assessments

### Flubenol 50 mg/g Oral Powder for Pigs

Vm 00879/4183

01 October 2025	Change to the dimensions of the polypropylene container for the Finished Product.
16 September 2025	One-off alignment of the product information with version 9.0* of the QRD templates.
14 April 2025	Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV).
18 June 2024	Deletion of titanium dioxide as a component or components of the colouring system.
25 January 2024	Deletion of a packaging site for the finished product.
30 October 2023	Deletion of a manufacturing site responsible for manufacturing, primary packaging, secondary packaging, labelling, QC & stability testing and QP batch release.
18 January 2023	Submission of an updated certificate of suitability.
01 September 2022	Addition of a batch release site for the finished product. Addition of a batch release site for the finished product. Addition of a manufacturing site of the finished product.
01 September 2022	Additional site for QC testing of the finished product. Additional site for QC testing of the finished product. Additional site for QC and stability testing of the finished product. Deletion of a non-significant specification parameter of the finished product.
11 June 2021	Addition of a secondary packaging site of the finished product. Addition of a primary packaging site of the finished product.
01 October 2020	Change of Marketing Authorisation Holder from Eli Lilly and Company Limited, Lilly House, Priestley Road, Basingstoke, Hampshire, RG24 9NL to Elanco Europe Ltd, Form 2, Bartley Way, Bartley Wood Business Park, Hook, RG27 9XA, United Kingdom.
05 June 2019	Change in the safety database of an existing pharmacovigilance system as described in the DDPS.
10 May 2018	Submission of an updated Ph. Eur. certificate of suitability for an active substance from an already approved manufacturer.
09 April 2015	Submission of an updated certificate of suitability.
14 March 2013	Amendments to the SPC and Product Literature
20 June 2012	Change of MAH
21 March 2012	Change in specification of the active substance Submission of an updated Ph. Eur. Certificate of

	Suitability for an active substance from an already approved manufacturer
07 March 2012	Change of distributor
26 April 2011	Introduction of a retest period of 60 months and storage conditions of 'Do not store above 30°C' for the active substance
16 February 2011	Submission of 2 updated Ph. Eur. Certificates of Suitability for an active substance from an already approved manufacturer
16 February 2010	Addition of a manufacturer of the active substance
30 January 2010	Deletion of an assembler of the dosage form
07 April 2009	Harmonisation of the SPC
06 March 2008	Replacement of two manufacturing sites for the finished product
27 February 2008	Change of address of the MAH
23 January 2008	Change of legal category from MFX to POM-VPS Changes to the SPC and Product Literature to bring in line with new legislation Addition of an indication against <i>Strongyloides ransomi</i>
02 November 2007	Replacement of the two manufacturing sites of the finished product
09 October 2007	Change in batch size of the finished product
30 November 2006	Minor change in the manufacturing process of the finished product
18 September 2006	Submission of a new Ph. Eur. Certificate of Suitability for an active substance
05 July 2006	Change of in-process controls implemented during the manufacture of the finished product Change of specification for the finished product Change in manufacturing process of the finished product
21 June 2006	Renewal
05 June 2006	Change in batch size of the finished product Change of address of the manufacturer and assembler of the dosage form
17 March 2006	Change in composition of the packaging
27 July 2005	Submission of a Ph. Eur. Certificate of Suitability for an active substance
18 March 2004	Change of dosage particulars